Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab

Sade-Feldman, Moshe, Kanterman, Julia, Klieger, Yair, Ish-Shalom, Eliran, Olga, Mizrahi, Saragovi, Amijai, Shtainberg, Hani, Lotem, Michal, Baniyash, Michal · 2016 · Clinical Cancer Research

Abstract

Purpose: High levels of circulating myeloid-derived suppressor cells (MDSCs) in various cancer types, including melanoma, were shown to correlate with poor survival. We investigated whether frequencies of circulating CD33+CD11b+HLA-DR− MDSCs could be used as immune system monitoring biomarkers to predict response and survival of patients with stage IV melanoma treated with anti-CTLA4 (ipilimumab) therapy. Experimental Design: Peripheral blood samples from 56 patients and 50 healthy donors (HDs) were analyzed for CD33+CD11b+HLA-DR− MDSC percentage, NO−, and hROS levels by flow cytometry. We determined whether MDSC levels and suppressive features detected before anti-CTLA4 therapy correlate with the patients' response and overall survival (OS). Results: Patients with melanoma had significantly higher levels of circulating CD33+CD11b+HLA-DR− MDSCs with suppressive phenotype when compared with HDs. Low levels of MDSCs before CTLA-4 therapy correlated with an objective clinical response, long-term survival, increased CD247 expression in T cells, and an improved clinical status. No predictive impact was observed for lactate dehydrogenase (LDH). Kaplan–Meier and log-rank tests performed on the 56 patients showed that the presence of more than 55.5% of circulating CD33+CD11b+ out of the HLA-DR− cells, were associated with significant short OS (P < 0.003), a median of 6.5 months, in comparison with the group showing lower MDSC frequencies, with a median survival of 15.6 months. Conclusions: Our study suggests the use of CD33+CD11b+HLA-DR− cells as a predictive and prognostic biomarker in patients with stage IV melanoma treated with anti-CTLA4 therapy. This monitoring system may aid in the development of combinatorial modalities, targeting the suppressive environment in conjunction with iplimumab, toward facilitating better disease outcomes. Clin Cancer Res; 22(23); 5661–72. ©2016 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-3104

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 43 references

Cited by

See all 201

Metadata

Authors
Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M.
Affiliations
  • Hebrew University of Jerusalem (IL)
  • 2ImProDia Ltd., Herzliya Pituah, Israel.
  • Hadassah Medical Center (IL)
Venue
Clinical Cancer Research
Published
2016-11-30
Volume
22
Issue
23
Pages
5661-5672
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2533098748
Cited by
201
References
43
Citations by year
2026: 8 · 2025: 14 · 2024: 15 · 2023: 21 · 2022: 23 · 2021: 23 · 2020: 34 · 2019: 21 · 2018: 19 · 2017: 18 · 2016: 5
FWCI
12.70
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
myeloid-derived suppressor cells, stage IV melanoma, ipilimumab, CTLA-4 blockade, predictive biomarkers, prognostic factors, overall survival, immune monitoring, CD247, tumor microenvironment, immunotherapy response
MeSH terms
Ipilimumab, Female, HLA-DR Antigens, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Prognosis, T-Lymphocytes, Biomarkers, Tumor, Myeloid Cells, CD11b Antigen, CTLA-4 Antigen, Sialic Acid Binding Ig-like Lectin 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-3104
The paper
Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M. (2016). Clinical Significance of Circulating CD33+CD11b+HLA-DR− Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-3104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.